NCT06194955 (H-21044858) is a NA clinical trial of GIP(1-42) in Incretin Effect, sponsored by University of Copenhagen.

Who is sponsoring NCT06194955?

NCT06194955 is sponsored by University of Copenhagen.

What drugs are being tested in NCT06194955?

Interventions in NCT06194955: GIP(1-42), GLP-1, GLP-2, Placebo.

What condition does NCT06194955 study?

NCT06194955 studies Incretin Effect.

Is NCT06194955 still recruiting?

NCT06194955 is currently completed. Last updated 28 April 2026.

Last reviewed 2026-04-28 · How we verify

NCT06194955: H-21044858

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon-like Peptide-1 (GLP-1) and Glucagon-like Peptide-2 (GLP-2) in Individuals With Genetically Altered Receptor Function

Completed NA Last updated 28 April 2026

What this trial tests

NA trial testing GIP(1-42) in Incretin Effect in 50 participants. Completed in 1 April 2026.

Timeline

4 January 2023

Primary endpoint
10 December 2025

1 April 2026

Quick facts

Lead sponsor	University of Copenhagen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	basic science
Enrollment	50
Start date	4 January 2023
Primary completion	10 December 2025
Estimated completion	1 April 2026
Sites	1 location across Denmark

Drugs / interventions tested

GIP(1-42) — full drug profile →
GLP-1 — full drug profile →
GLP-2 — full drug profile →
Placebo

Conditions studied

Incretin Effect — all drugs for Incretin Effect →

Sponsor

University of Copenhagen

Who can join

Adults 18 to 80, any sex, with Incretin Effect. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

For GIP- and GLP-1 receptor variants: Insulinotropic effect (C-peptide)
Time frame: 240 minutes
Blood sample
For GLP-2 receptor variants: CTX (bone resorption marker)
Time frame: 120 minutes
Blood sample

Sponsor's own description

This project will characterize the physiological effect of the hormones, GIP-, GLP-1- and GLP-2 infusions in a group of individuals that are carriers of GIP-, GLP-1- and GLP-2 receptor gene variants, respectively.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Transforming obesity: The advancement of multi-receptor drugs.
Kusminski CM, Perez-Tilve D, Müller TD, DiMarchi RD, et al · · 2024 · cited 77× · PMID 39059360 · DOI 10.1016/j.cell.2024.06.003

Verify or expand the search:

Other trials of GIP(1-42)

Trials testing the same drug.

NCT06934473 — Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals · NA · recruiting
NCT04792762 — Physiology of GIP(1-30)NH2 in Humans · NA · completed

Other University of Copenhagen trials

Trials by the same sponsor.

NCT07461324 — Surgeons' Prediction of Dental Surgery Complications and the Influence of Patient Characteristics: Development of an AI · not yet recruiting
NCT07389421 — School Meals in Denmark · NA · not yet recruiting
NCT07450690 — Exercise Training Effects on Muscle Function in Adults With Mitochondrial Myopathy · NA · recruiting
NCT07302880 — The Acute Interference of Biotin in Blood Analysis · NA · not yet recruiting
NCT07312981 — The CPH-MBD Cohort Dietary Substudy - Comparison of Methods for Dietary Registrations · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06194955 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Copenhagen
Last refreshed: 28 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06194955.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing